Schizophrenia

Antipsychotic dose reductions can increase mental illness and all-cause hospitalizations, but the effects on tardive dyskinesia were unclear.

Recent studies questioned the benefits of second-generation antipsychotics, prompting researchers to reassess the risks of tardive dyskinesia from the use of first- and second-generation antipsychotics.

Study findings may facilitate new studies on the neural markers of tardive dyskinesia.

Meeting with a peer support worker to complete a personal recovery workbook reduced readmissions over a year for patients with mental health challenges.

The long-acting injectable risperidone (Perseris) will provide an alternative to daily oral medication to improve treatment adherence for patients with schizophrenia.

Three-quarters of patients who discontinue antipsychotic treatment experience relapse within 12-18 months. However, there are no current clinical guidelines describing treatment continuation or discontinuation beyond 1-2 years.

The new formulation allows patients with schizophrenia to begin treatment with just one oral dose of aripiprazole, achieving relevant levels in 4 days.

Researchers from McGill University say they’ve found genetic variants in patients with childhood-onset schizophrenia, offering a new direction for the development of treatment drugs.

People living with mental illness face great adversity. One of their greatest challenges is the seemingly intractable problem of stigma.

Researchers in Baltimore found a connection between prenatal complications, genetic risk, and the impact on neurodevelopmental conditions in children.

David Walling, PhD, discussed the biggest misconceptions about patients with schizophrenia, including the high rate of suicide among this population.

David Walling, PhD, discussed the results from a pharmacokinetic and safety study that evaluated aripiprazole lauroxil NanoCrystal Dispersion therapy initiation.

Firearm use in the not guilty by reason of insanity population is more closely related to substance use and personality disorder than psychotic or mood disorders.

Women with PCOS face increased risk of psychiatric morbidity and their children are more likely to be diagnosed with ADHD or autism.

Relive the 10 biggest headlines in this year of clinical news.

A new study suggests the novel therapy can help empower patients with psychoses.

Risks increase when a child’s mother, versus their father has a history of homelessness.

The FDA has approved aripiprazole tablets with a sensor to digitally track whether patients have taken their medication.

More than double the number of patients experienced relapse with placebo compared to cariprazine.

ARISTADA is being investigated as a possible extended-release injectable suspension, as well as INVEGA SUSTENNA in patients with acute exacerbation of schizophrenia.

The drug showed improved symptoms across multiple doses in a 6-month study.